MD, University of Oslo, Oslo, Norway - 1987
PhD, Pathology, University of Oslo, Norway
Expertise & Research Interests
Dr. Rui has made a series of
contributions to increased understanding of the molecular mechanisms of signal transduction by receptors for prolactin and related cytokines and hormones. Dr. Rui was the first to isolate a prolactin receptor-associated tyrosine kinase, and to identify this molecule as Janus kinase-2. Dr. Rui's laboratory has maintained a focus o要 prolactin receptor function with a primary goal of understanding the role of downstream Jak-Stat pathways and their aberrations in breast cancer.
Activation of Stat5 is a strong favorable prognostic marker in breast cancer and an invasion-suppressive role of Stat5 in human breast cancer may represent a biological mechanism. Loss of Stat5 is further associated with increased risk of antiestrogen resistance. Dr. Rui and his team have also invented and applied a new technology to generate high density tumor tissue arrays for high-through-put molecular profiling. Dr. Rui is the PI of a $6.7 million, 5 year Komen Promise Grant to a consortium of multidisciplinary investigators to classify malignant breast tumors based o要 expression of druggable target proteins for improved personalized cancer care. The consortium project also involves a novel Bayesian adaptive biomarker-centered Phase II clinical trial of a Parp-inhibitor in the neoadjuvant setting for triple-negative breast cancer.
Cancer Biology Profile Recent Publications via Scoups
Keywords: cancer; breast cancer; hormone; endocrinology; prolactin; growth hormone; estrogen; glucocorticoid; steroid hormones; Jak2; Stat5; Stat5a; Stat5b; immunohistochemistry; pathology; biomarker; early detection; microarray; tissue microarray; mouse modeling; EGFR; Her2; ErbB2; prolactin receptor;
Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H. Epithelial defect in prostates of Stat5a null mice. Lab Invest, 80, 993-1006, 2000 (cited > 10 times).
Kirken RA, Erwin RA, Wang L, Rui H, Farrar WL.Functional uncoupling of the Jak3-Stat5 pathway in malignant growth of HTLV-1 transformed human T-cells. Journal of Immunology, 165:5097-104, 2000 (cited > 15 times).
Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon G, Hennighausen L, Kirken RA, Rui H.Role of serine phosphorylation of Stat5a in prolactin-stimulated b-casein gene expression. Molecular and Cellular Endocrinology, 183:151-163, 2001 (cited > 20 times).
Park S-H, Yamashita H, Rui H, Waxman DJ. Serine phosphorylation of growth hormone-activated STAT5a and STAT5b: Impact o要 STAT5 transcriptional activity. Molecular Endocrinology, 15:2157-71, 2001 (cited > 20 times).
Ahonen TJ, Harkonen P, Rui H, Nevalainen MT. Prolactin signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology, 143:228-238, 2002 (cited 9 times).
Xie J, LeBaron MJ, Nevalainen MT, Rui H. Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells.Journal of Biological Chemistry, 277, 14020-14030, 2002 (cited 10 times).
Nevalainen MT, Xie J, Bubendorf L, Wagner K-U, Rui H.Basal activation of transcription factor Stat5 in non-pregnant mouse and human breast epithelium.Molecular Endocrinology, 16, 1108-1124, 2002 (cited >15 times).
Boer A-K, Drayer AL, Rui H, Vellenga E. Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB.Blood, 100, 476-73, 2002 (cited >15 times).
Nagy ZS, Erwin-Cohen RA, Wang L, Aradi J, Monia B, Stepkowski SM, Rui H, Kirken RA. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro-motif of Stat5 transcription factors in human T cells: Resistance to suppression of multiple serine kinase pathways. Journal of Leukocyte Biology, 72, 819-28, 2002 (cited > 10 times).
Benitah SA, Valeron PF, Rui H, Lacal JC.STAT5a Activation Mediates the Epithelial to Mesenchymal Transition Induced by o要cogenic RhoA. Mol Biol Cell, 14: 40-53, 2003(cited 9 times) .
Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT. Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells. J Biol Chem, 278: 27287-92, 2003 (cited > 10 times).
Uddin S, Lekmine F, Sassano A, Rui H, Fish EN, Platanias LC. Role of Stat5 in Type I interferon-signaling and transcriptional regulation. Biochem Biophys Res Commun, 308: 325-30, 2003 (cited > 10 times).
Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H. Signal Transducer and Activator of Transcription-5 activation and breast cancer prognosis. Journal of Clinical o要cology, 22, 2053-2060, 2004 (cited 8 times).
Wagner K-U, Krempler A, Triplett AA, Qi Y, George NM, Zhu J, Rui H. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice.Molecular Cell Biology, 24, 5510-5520, 2004 (cited > 10 times).
Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner K-U. Generation of a conditional knockout allele for the Janus Kinase 2 (Jak2) gene in mice.Genesis, 40, 52-57, 2004.
Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Transcription factor Stat5 stimulates homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. o要cogene, 24, 746-760, 2005.
LeBaron MJ, Xie J, Rui H. Evaluation of a genome-wide Chromatin library of Stat5 binding sites in human breast cancer.Molecular Cancer, 4:6, 2005; doi: 10.1186/1476-4598-4-6 (10 pages).
LeBaron MJ, Crismon HR, Utama FE, Neilson LM, Sultan AS, Johnson KJ, Andersson EC, Rui H. Ultrahigh density microarrays of solid samples. Nature Methods 2, 511-513, 2005. Comment in: Nature Methods. 2,492-3,2005 (cited 3 times).
Finkel TH, Selliah N, Zhang M, DeSimone D, Brunner M, Ittenbach RF, Rui H, Cron R. The γc-Cytokine regulated transcription factor, Stat5, increases HIV-1 production in primary CD4 T-cells. Virology, 344,283-91,2006.
Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner K-W, Rui H. Human prolactin receptors are insensitive to mouse prolactin: Implications for xenotransplant modeling of human breast cancer in mice. Journal of Endocrinology, 188,589-601,2006.
Maintained by the Informatics Shared Resources at the Kimmel Cancer Center at Jefferson
Copyright© Thomas Jefferson University. All Rights Reserved.
The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement